Lionheart Health, Inc. has been recognized as a finalist in the category of Best Innovation in Medical Technology Life Sciences in Octane's prestigious High Tech Awards. This acknowledgment underscores the company's commitment to developing breakthrough healthspan longevity solutions that could fundamentally transform human aging and healthcare.
The company's flagship development is a revolutionary whole body regeneration chamber described as a "womb for adults" designed to extend healthspan longevity by 20 years. Powered by artificial intelligence and precise robotics, this multi-modality device utilizes bioelectrically-controlled and enhanced biologics to regenerate multiple organs including hearts, kidneys, brains, livers, pancreas, lungs, and other critical systems. This technology represents a paradigm shift in regenerative medicine with potential implications for treating age-related diseases and improving quality of life for aging populations worldwide.
Lionheart Health's business model focuses on licensing its patented technology platform to qualified clinics globally. The company has already secured FDA 510K market clearances for using targeted bioelectric stimulation to improve circulation, build muscle strength, reduce pain and inflammation, treat arthritis, prevent blood clots, enhance exercise benefits, and improve stroke recovery. These regulatory approvals validate the scientific foundation of their approach and open doors for widespread clinical adoption.
The recognition from Octane, a pivotal connector in the innovation ecosystem known for fostering relationships and capital growth, positions Lionheart Health at the forefront of Orange County's emerging reputation as a significant hub for disruptive healthcare innovation. This award nomination follows several other recent honors, including the AbbVie Allergan ULP Innovation in Medical Aesthetics Award and Medtech Outlook Stimulator Development of the Year 2025 Award. The company is also among 40 semi-finalists in the $101 million XPRIZE Healthspan Competition, further validating the significance of their technological advancements.
Howard Leonhardt, Executive Chairman and Co-CEO, stated that this acknowledgment reflects their dedication to advancing longevity and healthspan through innovation. The company's research demonstrates that exercising with their patented BodStim TM EMS suit can substantially increase circulating klotho levels compared to ordinary exercise, potentially slowing the aging process. Those interested in learning more about klotho levels can visit https://www.klothoyears.com to order testing.
The implications of Lionheart Health's innovations extend beyond individual health benefits to potentially reducing healthcare costs associated with age-related diseases and changing how society approaches aging. As the global population continues to age, technologies that can extend healthspan while compressing morbidity could have profound economic and social impacts. The upcoming Octane 2025 Technology Awards Ceremony on September 25th, 2025 in Irvine will further highlight these advancements, with registration available at https://www.octane-oc.org/event/e891a457-c212-43fa-9c31-c35a57002cd9/2025-finalists.
